ProMIS Neurosciences Inc. Common Shares (ON)
$14.01
$0.55 (+4.09%)
$13.52Day Range$14.21
Key Statistics
Market Cap
$125.64M
Shares Outstanding
9.0M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Sep 30, 2005
Round Lot
100
Locale
US
Trading Data
Day Open
$13.52
Day High
$14.21
Day Low
$13.52
Volume
24.5K
VWAP
$14.01
Prev Close
$13.46
Transactions
--
Acc. Volume
--
About ProMIS Neurosciences Inc. Common Shares (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.
PHARMACEUTICAL PREPARATIONSSIC 283411 employeesSUITE 200, 1920 YONGE STREET, TORONTO, A6, M4S 3E2416-847-6898IPO Sep 30, 2005US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001374339
- Composite FIGI
- BBG000R0MF47
- Share Class FIGI
- BBG001SMDG62
- Ticker Root
- PMN
- SIC Code
- 2834
About ProMIS Neurosciences Inc. Common Shares (ON) (PMN) Stock
ProMIS Neurosciences Inc. Common Shares (ON) (PMN) closed the 2026-09-18 session at $14.01, up 4.09% versus the previous close (+0.55). The stock opened at $13.52 and traded between $13.52 and $14.21 during that session. Session trading volume was 24K shares. The volume-weighted average price (VWAP) is $14.01.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.
ProMIS Neurosciences Inc. Common Shares (ON) has a market capitalization of $125.6 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. PMN is listed on the XNAS exchange. The company employs approximately 11 people. ProMIS Neurosciences Inc. Common Shares (ON) is headquartered in TORONTO, A6. The recorded listing date is 2005-09-30.
On this page you can find market PMN stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.